# Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation

> **NCT02232880** · PHASE2 · TERMINATED · sponsor: **Vanderbilt University Medical Center** · enrollment: 1 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Abatacept
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02232880
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-08
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** failure to recruit
- **Last updated:** 2017-02-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02232880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02232880, "Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02232880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*